Frontiers in Cellular and Infection Microbiology (Apr 2019)
Dysbiosis of the Gut Microbiome in Lung Cancer
- He Zhuang,
- He Zhuang,
- He Zhuang,
- Liang Cheng,
- Liang Cheng,
- Yao Wang,
- Yao Wang,
- Yao Wang,
- Yu-Kun Zhang,
- Yu-Kun Zhang,
- Yu-Kun Zhang,
- Yu-Kun Zhang,
- Man-Fei Zhao,
- Man-Fei Zhao,
- Man-Fei Zhao,
- Man-Fei Zhao,
- Gong-Da Liang,
- Gong-Da Liang,
- Gong-Da Liang,
- Gong-Da Liang,
- Meng-Chun Zhang,
- Meng-Chun Zhang,
- Meng-Chun Zhang,
- Yong-Guo Li,
- Jing-Bo Zhao,
- Yi-Na Gao,
- Yu-Jie Zhou,
- Yu-Jie Zhou,
- Yu-Jie Zhou,
- Shu-Lin Liu,
- Shu-Lin Liu,
- Shu-Lin Liu,
- Shu-Lin Liu,
- Shu-Lin Liu
Affiliations
- He Zhuang
- Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China
- He Zhuang
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- He Zhuang
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- Liang Cheng
- Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China
- Liang Cheng
- College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China
- Yao Wang
- Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China
- Yao Wang
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Yao Wang
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- Yu-Kun Zhang
- Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China
- Yu-Kun Zhang
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Yu-Kun Zhang
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- Yu-Kun Zhang
- Department of Colorectal Cancer, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China
- Man-Fei Zhao
- Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China
- Man-Fei Zhao
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Man-Fei Zhao
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- Man-Fei Zhao
- Department of Epidemiology, Public Health School, Harbin Medical University, Harbin, China
- Gong-Da Liang
- Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China
- Gong-Da Liang
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Gong-Da Liang
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- Gong-Da Liang
- Department of Epidemiology, Public Health School, Harbin Medical University, Harbin, China
- Meng-Chun Zhang
- Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China
- Meng-Chun Zhang
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Meng-Chun Zhang
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- Yong-Guo Li
- Department of Infectious Diseases, The First Affiliated Hospital, Harbin Medical University, Harbin, China
- Jing-Bo Zhao
- Department of Epidemiology, Public Health School, Harbin Medical University, Harbin, China
- Yi-Na Gao
- Department of Respiration, The Third Affiliated Hospital of Harbin Medical University, Harbin, China
- Yu-Jie Zhou
- Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China
- Yu-Jie Zhou
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Yu-Jie Zhou
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- Shu-Lin Liu
- Systemomics Center, College of Pharmacy, and Genomics Research Center (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, China
- Shu-Lin Liu
- HMU-UCCSM Centre for Infection and Genomics, Harbin Medical University, Harbin, China
- Shu-Lin Liu
- Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medical Sciences, Harbin, China
- Shu-Lin Liu
- Department of Epidemiology, Public Health School, Harbin Medical University, Harbin, China
- Shu-Lin Liu
- Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada
- DOI
- https://doi.org/10.3389/fcimb.2019.00112
- Journal volume & issue
-
Vol. 9
Abstract
Lung cancer (LC) is one of the most serious malignant tumors, which has the fastest growing morbidity and mortality worldwide. A role of the lung microbiota in LC pathogenesis has been analyzed, but a comparable role of the gut microbiota has not yet been investigated. In this study, the gut microbiota of 30 LC patients and 30 healthy controls were examined via next-generation sequencing of 16S rRNA and analyzed for diversity and biomarkers. We found that there was no decrease in significant microbial diversity (alpha diversity) in LC patients compared to controls (P observed = 0.1422), while the composition (beta diversity) differed significantly between patients and controls (phylum [stress = 0.153], class [stress = 0.16], order [stress = 0.146], family [stress = 0.153]). Controls had a higher abundance of the bacterial phylum Actinobacteria and genus Bifidobacterium, while patients with LC showed elevated levels of Enterococcus. These bacteria were found as possible biomarkers for LC. A decline of normal function of the gut microbiome in LC patients was also observed. These results provide the basic guidance for a systematic, multilayered assessment of the role of the gut microbiome in LC, which has a promising potential for early prevention and targeted intervention.
Keywords
